Evidence map›Paper›PMID 31430423›Full record

ArticleStem cells (Dayton, Ohio)2019

Bcl2-Expressing Quiescent Type B Neural Stem Cells in the Ventricular-Subventricular Zone Are Resistant to Concurrent Temozolomide/X-Irradiation.

Brent D Cameron, Geri Traver, Joseph T Roland, Asa A Brockman, Daniel Dean, Levi Johnson, Kelli Boyd, Rebecca A Ihrie, Michael L Freeman

Open access · hybridAbstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Molecular mechanisms of astragaloside‑IV in cancer therapy (Review).International journal of molecular medicine · 2021
    Review
  11. Article
  12. Review
  13. A Preview of Select Articles.Stem cells translational medicine · 2020
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Brent D CameronDepartment of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Geri TraverDepartment of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Joseph T RolandDepartment of Surgical Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Asa A BrockmanDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Daniel DeanDepartment of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Levi JohnsonDepartment of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Kelli BoydComparative Pathology, Division of Animal Care, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Rebecca A IhrieDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Michael L FreemanDepartment of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.ORCID 0000-0002-1375-1124
Vanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
THREE-TIERED PREVENTION MODEL TO BETTER SERVE ALL STUDENP30HD015052 · NICHD · VANDERBILT UNIVERSITY · PI HARRELL, FRANK E. · 1985 to 2014
$18.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Quantifying Differences in mTOR Activity and Tumor Development Between Neural Stem Cell MicrodomainsR01NS096238 · NINDS · VANDERBILT UNIVERSITY · PI IHRIE, REBECCA A · 2016 to 2020
$1.7M
Targeting Radiation Resistance in Glioblastoma Stem CellsR01CA166492 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FREEMAN, MICHAEL L. · 2013 to 2017
$1.6M
Leica Bond RXS10OD023475 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOYD, KELLI L. · 2018 to 2018
$213k
NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA166492NEI NIH HHS P30 EY008126NICHD NIH HHS P30 HD015052NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIH HHS S10 OD023475NINDS NIH HHS R01 NS096238
6 · The paper itself

Abstract

The ventricular-subventricular zone (V-SVZ) of the mammalian brain is a site of adult neurogenesis. Within the V-SVZ reside type B neural stem cells (NSCs) and type A neuroblasts. The V-SVZ is also a primary site for very aggressive glioblastoma (GBM). Standard-of-care therapy for GBM consists of safe maximum resection, concurrent temozolomide (TMZ), and X-irradiation (XRT), followed by adjuvant TMZ therapy. The question of how this therapy impacts neurogenesis is not well understood and is of fundamental importance as normal tissue tolerance is a limiting factor. Here, we studied the effects of concurrent TMZ/XRT followed by adjuvant TMZ on type B stem cells and type A neuroblasts of the V-SVZ in C57BL/6 mice. We found that chemoradiation induced an apoptotic response in type A neuroblasts, as marked by cleavage of caspase 3, but not in NSCs, and that A cells within the V-SVZ were repopulated given sufficient recovery time. 53BP1 foci formation and resolution was used to assess the repair of DNA double-strand breaks. Remarkably, the repair was the same in type B and type A cells. While Bax expression was the same for type A or B cells, antiapoptotic Bcl2 and Mcl1 expression was significantly greater in NSCs. Thus, the resistance of type B NSCs to TMZ/XRT appears to be due, in part, to high basal expression of antiapoptotic proteins compared with type A cells. This preclinical research, demonstrating that murine NSCs residing in the V-SVZ are tolerant of standard chemoradiation therapy, supports a dose escalation strategy for treatment of GBM. Stem Cells 2019;37:1629-1639.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingApoptosisChemoradiotherapyDisease Models, AnimalDNA Breaks, Double-StrandedDNA RepairDrug ResistanceFemaleGlioblastomaLateral VentriclesMaleMiceMice, Inbred C57BLNeural Stem CellsNeurogenesisAntineoplastic Agents, AlkylatingBcl2 protein, mouseProto-Oncogene Proteins c-bcl-2TemozolomideApoptosisGlioblastomaIonizing radiationNeural stem cellsSubventricular zoneTemozolomide

Identifiers

PMID31430423
PMCPMC6916634
OpenAlexW2980621697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.